Clin Exp Vaccine Res.
2022 May;11(2):173-183. 10.7774/cevr.2022.11.2.173.
SARS-CoV-2 vaccine challenge based on spike glycoprotein against several new variants
- Affiliations
-
- 1Department of Microbiology, Faculty of Medicine and Health, Universitas Muhammadiyah Jakarta, South Jakarta, Indonesia
- KMID: 2534988
- DOI: http://doi.org/10.7774/cevr.2022.11.2.173
Abstract
- The coronavirus disease 2019 pandemic has not ended, and several variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus continue to emerge. The emergence of new variants is worrying because higher transmission leads to spikes in infections, vaccine efforts, and other therapeutic developments. Existing literature reports that with new variants affecting vaccine efficacy, hospitalization and risk of a recurrent infection increase. In this review article, we describe the latest variants of SARS-CoV-2, and the impact of each new variant on the efficacy of the developed vaccines reported in the literature and findings. The report concludes that the emergence of a variant that completely evades the immune response and reduces neutralizing antibodies.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Will Mutations in the Spike Protein of SARS-CoV-2 Lead to the Failure of COVID-19 Vaccines?
- Recombinant proteins of spike protein of SARS-CoV-2 with the Omicron receptor-binding domain induce production of highly Omicron-specific neutralizing antibodies
- SARS-CoV-2 Delta (B.1.617.2) Variant: A Unique T478K Mutation in Receptor Binding Motif (RBM) of Spike Gene
- Genetic diversity and evolutionary patterns of SARSCoV-2 among the Bhutanese population during the pandemic
- Changes in SARS-CoV-2 antibody titers 6 months after the booster dose of BNT162b2 COVID-19 vaccine among health care workers
